In June 2020, a 54-year-old female presented with severe fatigue that had been worsening
over the past few weeks. She had a history of primary triple positive (lupus anticoagulant,
anticardiolipin and anti-β2GP1 antibodies) antiphospholipid syndrome (APS) revealed
19 years ago by a venous thromboembolism, and had been long-term treated with warfarin.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.Arthritis Rheum. 2002; 46: 1019‑1027
- Evolving adrenal dysfunction after bilateral adrenal infarction: a case report.AACE Clin Case Rep. 2019; 5: e334-e339
- Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients.Medicine (Baltimore). 2003; 82: 106‑118
- Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction in the antiphospholipid syndrome: long-term outcome of 16 patients.J Clin Endocrinol Metab. 2013; 98: 3179‑3189
Article Info
Publication History
Published online: September 08, 2021
Robert G. Stern, MD, Section EditorFootnotes
Funding: None.
Conflict of Interest: None.
Authorship: All authors had access to the data and a role in writing this manuscript.
Identification
Copyright
© 2021 Elsevier Inc. All rights reserved.
